Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sands, Bruce; Peyrin-Biroulet, Laurent; Loftus, Edward; Danese, Silvio; Colombel, Jean-Frederic; TÖRÜNER, MURAT; Jonaitis, Laimas; Abhyankar, Brihad; Chen, Jingjing; Rogers, Raquel; Lirio, Richard; Bornstein, Jeffrey; Schreiber, Stefan

doi:10.1056/nejmoa1905725

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Sands B. E., Peyrin-Biroulet L., Loftus E. V., Danese S., Colombel J., TÖRÜNER M., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.381, sa.13, ss.1215-1226, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 381 Sayı: 13
Basım Tarihi: 2019
Doi Numarası: 10.1056/nejmoa1905725
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1215-1226
Ankara Üniversitesi Adresli: Evet

Özet

BackgroundBiologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking.